NFKB1 and neoplasm: Aberrant NF-κB activation in these malignant cells is not only driven by the inflammatory tumor microenvironment or by latent infection with EBV, but also by somatic mutations of key NF-κB regulators, such as classical IκB proteins [10,196,197,198].